Research programme: microbiome therapeutics - Seres Therapeutics

Drug Profile

Research programme: microbiome therapeutics - Seres Therapeutics

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seres Therapeutics
  • Developer Massachusetts General Hospital; Seres Therapeutics; University of Pennsylvania
  • Class Bacteria
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Inflammatory bowel diseases; Metabolic disorders; Metabolic syndrome

Most Recent Events

  • 16 Mar 2017 Seres Therapeutics has patent protection for microbiome therapeutics in USA
  • 10 Nov 2016 Seres Therapeutics has patent protection for microbiome therapeutics in USA
  • 12 Jul 2016 Seres Therapeutics and Emulate collaborate for the development of microbiome therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top